4th Quarter - Report

BOCKORNY GROUP, INC. for CVS HEALTH INC

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the corporate business model, Medicare Part D and anti-PBM legislation. Issues related to health care delivery system reforms, cost containment, medication adherence, restrictions on PBM cost saving tools like mail order, generics and restrictions on PBM audit practices. Privacy issues relating to the use of protected health information.HR 1367, FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act. S.867, Medicare Prescription Drug Program Integrity and Transparency Act of 2013 Issues Related to Healthcare Reform Implementation

LobbyistCovered position, as disclosed
MARTINA L. BRADFORD —
BLAIR C LARKINS —
CAROLYN MAYLE New —
NICOLE VENABLE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office

Bills named: S. 867 (113th), H.R. 1367 (113th)

Labor Issues/Antitrust/Workplace LBR

Issues relating to a proposed anti-trust exemption for certain pharmacies, healthcare competition and the CVS Caremark business model

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
CAROLYN MAYLE New —
TODD THORPE —
NICOLE VENABLE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; White House Office

Medicare/Medicaid MMM

H.R.2960, Medicare Prescription Drug Integrity Act of 2013 H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013 SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013 Issues related to plan design, reimbursement and cost savings proposals.

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
MARTINA L. BRADFORD —
BLAIR C LARKINS —
CAROLYN MAYLE New ... Committee (96-98)
NICOLE VENABLE —

Contacted: SENATE; White House Office; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2960 (113th), H.R. 2810 (113th)

Pharmacy PHA

Issues related to prescription drug abuse and drug supply chain safety. H.R. 3204, Drug Quality and Security Act H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013 S. 957, Drug Supply Chain Security ActS.959, Pharmaceutical Quality, Security, and Accountability Act

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
MARTINA L. BRADFORD —
BLAIR C LARKINS —
CAROLYN MAYLE New —
NICOLE VENABLE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; White House Office

Bills named: H.R. 1919 (113th), H.R. 3204 (113th), S. 957 (113th)

Taxation/Internal Revenue Code TAX

Issues related to restructuring of corporate tax rates.

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
CAROLYN MAYLE New —
NICOLE VENABLE —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.